logo-loader
RNS
Silence Therapeutics PLC

Silence Therapeutics - Silence Therapeutics Presents New Data

RNS Number : 9758D
Silence Therapeutics PLC
03 May 2017
 

Silence presents new data

 

3 May 2017

 

Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that it has presented new pre-clinical data generated using its GalNAc-siRNA platform technology, including the translation of effective liver target knockdown into higher species, at the TIDES: Oligonucleotides and Peptide Therapeutics meeting in San Diego. The presentation is available on the Company's website, www.silence-therapeutics.com.

 

Enquiries:

 

Silence Therapeutics plc

Ali Mortazavi, Chief Executive Officer

David Ellam, Chief Financial Officer

 

Tel:  +44 (0)20 3457 6900

Canaccord Genuity Limited (Nominated Adviser and Joint Broker)

Henry Fitzgerald-O'Connor/Emma Gabriel

 

Tel:  +44 (0)20 7523 8350

Peel Hunt LLP (Joint Broker)

James Steel/Oliver Jackson

 

Tel:  +44 (0)20 7418 8900

Media Enquiries:

FTI Consulting

Simon Conway/Brett Pollard/Stephanie Cuthbert

 

 

Tel: +44 (0) 20 3727 1000

 

Notes to Editors

 

About Silence Therapeutics plc

 

Silence Therapeutics develops a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Our proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using our enabling delivery systems, we have achieved an additional level of specificity by delivering our therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of our molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUGUQCAUPMPUP
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read